Shares of Merck & Co., Inc. rose 1.8% after Guggenheim increased its price target from $122 to $140, maintaining a buy rating. The company recently exceeded quarterly earnings and revenue estimates, setting FY2026 EPS guidance and declaring an $0.85 quarterly dividend. Despite a mixed analyst sentiment, with a consensus “Hold” rating and a lower average price target, several other firms have also upgraded Merck’s stock or raised their price targets recently.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
Merck & Co., Inc. (NYSE:MRK) Shares Up 1.8% Following Analyst Upgrade
Shares of Merck & Co., Inc. rose 1.8% after Guggenheim increased its price target from $122 to $140, maintaining a buy rating. The company recently exceeded quarterly earnings and revenue estimates, setting FY2026 EPS guidance and declaring an $0.85 quarterly dividend. Despite a mixed analyst sentiment, with a consensus “Hold” rating and a lower average price target, several other firms have also upgraded Merck’s stock or raised their price targets recently.